Up next

Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025? 

Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, an important barometer of the financial health of the sectors, has been under pressure with macro factors in the US on tariffs, tax & monetary policy, and drug pricing reforms contributing to uncertainty. But will the tide turn?

Arda Ural, EY America Life Sciences Leader, Ernst & Young (EY)

Featuring Arda Ural, EY America Life Sciences Leader, Ernst & Young (EY).

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights. Or get each episode through:

For a full list of the 2025 podcast episode schedule, click here.

You May Also Like

Drug Launches & Approvals in 2025: The Blockbuster Contenders

By
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal…

CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?

By
Sponsored by Vetter Pharma International GmbH What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and…

Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty? 

By
As evolving US trade policy looms, what are the demand–supply fundamentals now in the global market for active pharmaceutical ingredients (APIs)?  A look at the demand side—size, growth rates, and…

Biomanufacturing: How are Industry Capacity & Supply Chains Trending?

By
What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies, and is there too much capacity or is the market tight? Is biomanufacturing outsourcing…